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Most human thyroid cancers are differentiated papillary carcinomas (PTC). Papillary thy-
roid microcarcinomas (PTMC) are tumors that measure 1cm or less. This class of small
tumors has proven to be a very common clinical entity in endocrine diseases. PTMC may
be present in 30–40% of human autopsies and is often identiﬁed incidentally in a thyroid
removed for benign clinical nodules. Although PTMC usually has an excellent long-term
prognosis, it can metastasize to neck lymph nodes; however deaths related to this type of
thyroid tumor are very rare. Few data exist on molecular pathways that play a role in PTMC
development; however, two molecules have been shown to be associated with aggressive
PTMC. S100A4 (calcium-binding protein), which plays a role in angiogenesis, extracellular
matrix remodeling, and tumor microenvironment, is over-expressed in metastatic PTMC. In
addition, the BRAFV600E mutation, the most common genetic alteration in PTC, is present
in many PTMC with extra thyroidal extension and lymph node metastasis. Importantly,
recently developed selective [e.g., PLX4720, PLX4032 (Vemurafenib, also called RG7204)]
or non-selective (e.g., Sorafenib) inhibitors of BRAFV600E may be an effective treatment for
patients with BRAFV600E-expressing PTMCs with aggressive clinical–pathologic features.
Here, we summarize the clinical outcome, cancer genetics, and molecular mechanisms
of PTMC.
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INTRODUCTION
Thevastmajorityof humanthyroidcancersaredifferentiatedand
pathological examination reveals that most of these are papillary
thyroid cancers (PTC). The long-term prognosis and recom-
mended treatment for patients with PTC are dependent on the
stage of disease. Papillary thyroid microcarcinoma (PTMC) are
small thyroid tumors (≤1cm in diameter) that belong to the low-
risk well-differentiated PTC, which are probably of little clinical
signiﬁcance, and do not affect patient survival (Arem et al., 1999;
Lloyd et al., 2004; Pazaitou-Panayiotou et al., 2007; Shaha et al.,
2007). It is important to distinguish between PTMC in a clini-
callyrecognizedmalignantthyroidmicronoduleandanincidental
(asymptomatic) PTMC found after thyroidectomy performed for
other indications (e.g.,benign thyroid diseases) or during thyroid
ultrasound. Incidental PTMC has an outstandingly good progno-
sis and there is nearly no risk of recurrence or death from PTMC
(Sugitani and Fujimoto, 1999; Barbaro et al., 2005; McDougall
and Camargo, 2007). However, PTMC may be associated with
lymph node metastases at presentation and/or neck loco-regional
recurrences during follow-up (Pazaitou-Panayiotou et al., 2007).
Papillary thyroid microcarcinomas may be categorized as: (i)
PTMC found at autopsy or incidentally at histology, (ii) PTMC
found incidentally during thyroid or neck ultrasound and diag-
nosed before surgery by cytology on thyroid ﬁne needle aspira-
tion (FNA) material, and (iii) clinical PTMC (i.e., tumors whose
presenting symptoms were loco-regional or distant metastases).
PTMCs are found in otherwise normal thyroids or in multin-
odular goiters (MNGs), and they account for nearly 50% of new
cases of PTC (PTC accounts for over 80% of all human thyroid
cancers; Leenhardt et al., 2004; Davies and Welch, 2006; Xing,
2009).
Papillarythyroidmicrocarcinomasarealsoreferredtoassmall,
tiny, or minute carcinomas. Some authors suggest that PTMC
found at histology should be called “occult” papillary tumors
instead of carcinomas to reﬂect their benignity.
Theuseof ultrasound(US)intheassessmentof thyroiddisease
has greatly increased the detection of thyroid micro nodules not
detected at clinical examination (Ezzat et al., 1994; Papini et al.,
2011). Prospective studies have undertaken systematic evaluation
of thyroid nodules incidentally discovered by US and have cor-
related size and the US and color-Doppler (CD) ﬁndings with
the prevalence of cancer and its pathologic staging (Leenhardt
etal.,1999).SeveralrecentstudieshavesuggestedthatUS-detected
PTMC(Figure1)isadifferentdiseaseentityfromPTMCdetected
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at autopsy, based on the histological ﬁndings and on the exis-
tence of some cases with poor prognosis (Sugitani and Fujimoto,
1999; Yamashita et al., 1999; Papini et al., 2002; Chow et al.,
2003a; Pellegriti et al., 2004; Lo et al., 2006). The vast majority of
non-palpablethyroidnodulesidentiﬁedbyUSandcolor-Doppler
display a hypoechoic pattern, irregular margins, microcalciﬁca-
tions,and intranodular vascularity indicating risk for malignancy,
which can be conﬁrmed by cytological evaluation of FNA mater-
ial.Duetothenon-negligibleprevalenceof extra-capsulargrowth
and nodal metastasis,US-guided FNA should be performed on all
8–15mm hypoechoic nodules with irregular margins,intranodu-
lar vascular spots, or microcalciﬁcations. Non-palpable thyroid
lesions without US risk factors should be followed up after 6–
12months by repeating clinical and US evaluation (Papini et al.,
2002).
TREATMENT AND CLINICAL OUTCOME
Treatment of PTMC has been addressed in both European Thy-
roid Association (ETA; Pacini et al., 2006) and American Thy-
roid Association (ATA; Cooper et al., 2009) guidelines. When
PTMC is diagnosed preoperatively, routine total, or near-total
thyroidectomy is the main treatment to eradicate multifocal dis-
ease and decrease overall recurrence rate. ATA guidelines for
patients with differentiated thyroid cancer state that the bene-
ﬁt of radioiodine treatment appears to be restricted to patients
with larger tumors (>1.5cm) or residual disease after surgery.
There is no evidence that there is any beneﬁt of radioiodine treat-
ment in lower risk patients (deﬁned by the following criteria:
PTMC with no extension beyond the thyroid capsule, unifocal
tumor,noaggressivehistologicsubtypes,noextrathyroidalexten-
sion or angioinvasion, no local or distant metastases, complete
resection of macroscopic tumor, and no 131I uptake outside the
thyroid bed on the post-therapeutic whole-body scan if 131I was
administered; Jonklaas et al., 2006; Cooper et al., 2009). Instead,
therecommendationforradioactiveiodineissupportedbyastudy
(Sakorafas et al., 2007) that followed 27 of 380 (7.1%) patients
diagnosed with incidental PTMC (mean diameter 4.4mm) fol-
lowingthyroidsurgeryforbenignthyroiddisease(20patientswith
MNG, six patients with follicular adenoma, and one patient with
nodularhyperplasia;Sakorafasetal.,2007). Patientswithcytolog-
ical preoperative diagnosis of thyroid malignancy were excluded
from this study. In 11 patients (40.7%), the tumor was multi-
focal and in about half of them tumor foci were found in both
thyroid lobes. In two patients, PTMC inﬁltrated the thyroid cap-
sule. Total/near-total thyroidectomy was performed in all these
patients. All patients with incidental PTMC received suppression
therapy and 20 underwent adjuvant radioactive iodine therapy at
a dose of 80–100mCi based mainly on the presence of multifocal
PTMC and inﬁltration of the thyroid capsule. Follow-up (mean
4.56years, range 1–12years) was completed in 25 patients; all of
these were alive and disease-free. The authors of this study con-
cluded that PTMC is not an uncommon incidental ﬁnding after
surgery for benign thyroid lesions and that therefore the possibil-
ity of PTMC (in particular multifocal incidental PTMC) should
be considered in the management of patients with benign thyroid
disease.Also,total/near-totalthyroidectomyshouldbeconsidered
in patients with apparently benign nodular thyroid disease who
exhibit risk factors including ﬁndings from history and clinical
examination (i.e., development of hoarseness, progressive dys-
phagia or shortness of breath,rapid growth of the thyroid nodule,
especiallyif observedunderthyroidhormonesuppressivetherapy,
or presence of cervical lymphadenopathy) or suspicious ﬁndings
on preoperative imaging evaluation.
Importantly, whether individual tumor foci in patients with
multifocal PTC or PTMC are clonally related or they arise inde-
pendently is still controversial. While Shattuck et al. (2005)
demonstrated that individual tumor foci in patients with multifo-
calPTCoftenariseasindependenttumors,McCarthyetal.(2006)
FIGURE 1 | Ultrasound and histological characteristics of a papillary
thyroid microcarcinoma (PTMC) nodule. (A–B) Papillary thyroid
microcarcinoma (PTMC) nodule (5.8mm) with hypoechoic pattern,
microcalciﬁcations, well-deﬁned margins, and intrinsic vascularity. (C–D)
PTMC nodule (6.3mm) with isoechoic or mixed echo texture, cystic
elements, irregular margins, hypovascularity, and coarse or peripheral
calciﬁcations [also “taller than wider” in (D)]. (E–H) Histological features of
2mm encapsulated PTMC with classical-type features in a multinodular goiter
[arrows, (E–G)]: papillary structure with ﬁbrovascular stalk, nuclear grooves,
and nuclear pseudo inclusions (H).The tumor cells had pale eosinophilic
cytoplasm with the characteristic vesicular to ground glass appearing nuclei
(H) [Magniﬁcation: (E) 20×, (F) 40×, (G) 100×, and (F) 1000×].
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demonstratedthatmultifocalPTCoftenarisefromthesameclone.
Thus, intrathyroid metastasis may play an important role in the
spreadofPTCandPTMC(McCarthyetal.,2006),buttheoriginof
multifocal tumors is unclear. Remarkably, some studies (Baudin
et al., 1998; Chow et al., 2003a) have reported that the number
and the size of tumor foci in PTMCs correlated with lymph node
metastasesatclinicalpresentationandwithrecurrence,suggesting
that those pathologic features may represent relevant prognostic
indicatorsinpatientswithPTMC.Infact,PTMCmultifocalitycan
beassociatedwithhighfrequencyof bilateralinvolvementregard-
lessoftumorsize(Baudinetal.,1998).Evenwhenthereisextended
disease,theprognosisof patientswithPTMCsisexcellent,andthe
majority of studies report a mortality rate between 0 and 0.4%
andarecurrenceratebetween1.4and7.3%(Pazaitou-Panayiotou
et al.,2007). However,there is some controversy regarding clinical
outcome and treatment of PTMC, as evidenced in the following
selected studies:
(i) Ito et al. (2003) followed 162 patients with lesions ranging
from3to10mm.In58ofthese,theystudiedthesizeofPTMC
byultrasoundover5ormoreyears.Theyfoundnochangein
60.3%ofthesecases,adecreasein12.1%,and,intwopatients,
no identiﬁable cancer in two consecutive ultrasounds. Ito
et al. (2004) also reported that PTMCs ≥7m mw e r em o r e
likelytoshowlateralneckmetastasis,suggestingthatdetailed
US examination for lateral metastasis is necessary in patients
with a tumor measuring ≥7mm.
(ii) Hay et al. (1992) evaluated 535 patients with PTMC with a
median tumor size of 8mm. Two patients (0.4%) died, and
the 20-year tumor recurrence rate was 6%.
(iii) Roti et al. (2006) reported on 243 patients diagnosed with
PTMC. One group consisted of 52 patients diagnosed with
incidental PTMC following thyroidectomy for benign thy-
roid disease. The second group included 191 patients who
underwent thyroidectomy because FNA biopsy of a thyroid
nodule and/or clinical evaluation was diagnostic or suspi-
cious for malignancy. No signiﬁcant differences in clinical
andhisto-pathologicalcharacteristicswereobservedbetween
thetwogroups.MeanPTMCdiameterwas0.55±0.26cmin
theincidentalgroupand0.56±0.27cminthesuspectedcan-
cergroup.Atotalof 34patientshadnecknodeand/ordistant
metastases at the time of diagnosis. Distant metastases were
only signiﬁcantly observed in patients with PTMC≥8mm.
Thirty-two patients with PTMC with a diameter≥5mm,
and two with PTMC with a diameter<5mm had lymph
node metastases (Roti et al.,2006). Lymph nodes and distant
metastases from thyroid cancers with diameters of 8–15mm
have been also described in other studies (Lin et al., 1997;
Sugitani et al., 1998; Nasir et al., 2000). Interestingly, Roti
et al. (2006) reported only four patients (1.7%) with recur-
rent or persistent disease, and no PTMC-related mortality.
Similarly,anexcellentoutcomeforPTMChasbeendescribed
byotherinvestigators(BramleyandHarrison,1996;Noguchi
et al., 1996; Rodriguez et al., 1997; Yamashita et al., 1999;
Pelizzo et al., 2004), whereas other studies found persistent
orrecurrentdiseasein6–14.4%of patientswithPTMC(Hay
et al.,1992; Chow et al.,2003b; Pellegriti et al.,2004).
(iv) One major issue with PTMC is the threshold value of tumor
diameter and whether the outcome for slightly larger thyroid
tumors (i.e., 1.1–1.5cm in diameter) is similar to PTMC.
Pellegriti et al. (2004) investigated predictors of relapse in
PTMC vs. PTC between 1.1 and 1.5cm. The authors per-
formedaretrospectivestudyof299patientswithPTCtreated
and followed up between 1975 and 2001. Near-total or total
thyroidectomy was performed in 292 patients, and lobec-
tomy in seven patients. This study indicated that a high
proportion of PTC≤1.5cm carry one or more risk factors
at clinical presentation,including bilateral foci. In particular,
authors found that approximately 20% of small (≤1.5cm)
PTCs had extra-thyroid invasion and/or bilateral foci. None
of the 299 patients in this study died of the disease. How-
ever,43(14.4%)patientsstillhadpersisting/recurrentdisease
at the last follow-up visit. PTC were subdivided into three
groups according to their size (diameter: <0.5, 0.6–1.0, and
1.1–1.5cm)andaprogressivelyincreasingfrequencyof signs
of tumor aggressiveness (multifocality, bilaterality, extrathy-
roidal invasion, and lymph node involvement) which corre-
latedwithincreasingtumorsize.Thiswasparticularlyevident
for PTC greater than 1.0cm vs. PTC less 1.0cm in diameter
(Pellegriti et al.,2004).
(v) Presence or absence of risk factors/aggressiveness features
are important indicators in planning thyroid surgery for
PTMC (e.g., lobectomy alone vs. total thyroidectomy with
central compartment neck dissection). Previous studies have
shown considerable variability in the prevalence of aggres-
sive features and but signiﬁcant differences between PTMC
and PTC in the prevalence of aggressive features. This was
addressed in a recent study (Yun et al., 2010) that found
that out of 87 patients (preoperative retrospective study), 44
(51%) had extra thyroidal extension,and 27 (31%) had cen-
tral lymph node metastasis. Positron emission tomography
(PET)/Computed tomography (CT) showed discernible ﬂu-
orodeoxyglucose (FDG) uptake in 46 PTMCs (53%). FDG
positivity of PTMCs was the only variable that correlated
with both extra thyroidal extension and central lymph node
metastasis; there was a signiﬁcant difference in the preva-
lence of both extra thyroidal extension (70 vs. 29%) and
central lymph node metastasis (41 vs. 19.5%) between FDG-
positive and -negative groups. The authors concluded that
visual FDG positivity in PTMCs is a potential risk factor
that may be useful for preoperative risk stratiﬁcation. How-
ever, this study lacked long-term follow-up of correlation
of FDG positivity in PTMCs with disease relapse rate, thus
prospective studies are needed to assess the long-term bene-
ﬁt, cost effectiveness, sensitivity, and speciﬁcity of FDG-PET
in patients with PTMC.
(vi) Importantly, Biscolla et al. (2004) have reported that PTMC
can be associated with medullary thyroid cancer (MTC).
Twenty-seven of 196 (13.8%) MTC cases showed an asso-
ciation with PTC, and 21 of 190 (11%) MTC showed an
association with incidental PTMC. This percentage is higher
than that reported in the literature on the association of
PTMCwithGraves’disease(GD;2.8%–4.5%;Schwartzetal.,
1989; Mazzaferri, 1990; Hori et al., 1995; Merchant et al.,
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2002) or with MNG (3%; Pelizzo et al., 1997). The authors
excluded the possibility that this association was caused by
an increase in the general frequency of PTMC. Further-
more, although it was not possible to completely exclude
a shared pathogenic event as the cause of both MTC and
PTMC, the molecular analysis of RET gene alterations did
not show any common mutation between these two types
of thyroid cancers. The clinical behavior of MTC does not
seem to be inﬂuenced by the presence or speciﬁc thera-
peutic treatment of a concomitant PTMC (Biscolla et al.,
2004).
In summary, total or near-total thyroidectomy is the treatment
of choice in patients with PTC followed by radioactive iodine
ablation, in case of a tumor size greater than 1.0cm or the pres-
ence of lymph node or distant metastasis, to achieve negative
131I whole-body scan and undetectable thyroglobulin (Tg) lev-
els during follow-up. Levothyroxine (LT4) suppressive therapy is
recommendedforhighriskthyroidcancerspatients.Post-surgical
radioiodine treatment in the case of patients with PTMC (tumor
size less or equal to 1cm in diameter) is clearly indicated in the
presence of high risk factors, but can be avoided in patients with
low-risk (unifocal tumor,no extra thyroidal extension,no tall cell
variant,columnarcell,diffusesclerosing,andsolid/trabecularvari-
ants, and no lymph node, or distant metastases; Falvo et al., 2003;
Pazaitou-Panayiotou et al.,2007).
GENETIC ALTERATIONS IN PTMC
ThesearchformoleculartargetsforPTChasfocusedprimarilyon
the RET (tyrosine kinase receptor)/RAS/BRAF/MAPK (mitogen-
activated extracellular signal regulated kinase,i.e.,ERK1/2) kinase
signaling pathway as the oncogenic event in PTC progression
(Xing,2007;Nuceraetal.,2010,2011a,b;Knauf etal.,2011;Ringel,
2011). The major genetic alterations so far described in PTC are
translocations in the RET gene (the estimated prevalence is highly
variable between different studies, from 3 to 92%, and depends
on the experimental methodology used) and the V600E point
mutation in the BRAF gene (Nikiforova et al., 2003; Xing, 2007;
Marotta et al., 2011), which occurs in about 50% of PTC. Both
of these genetic alterations trigger the ERK1/2 pathway, which
causes abnormal cell proliferation,adhesion,migration,and inva-
sion (Melillo et al., 2005; Nucera et al., 2010, 2011b; Knauf et al.,
2011).
A high prevalence (about 45–52%) of RET/PTC translocations
hasbeenreportedinPTMCs(Tallinietal.,1998;Corvietal.,2001),
suggesting that the activation of this oncogene (RET/PTC) plays a
role in the early stage in PTMC development.
The BRAFV600E mutation appears to occur early in PTC devel-
opment, based on evidence that it is also harbored in PTMC
(Sedliarouetal.,2004;Xing,2007;Frascaetal.,2008;Nuceraetal.,
2009) and plays an important role in cell proliferation by regulat-
ing cyclins (e.g.,cyclins D1 and p27;Motti et al.,2007;Xing,2007;
Salerno et al., 2010; Nucera et al., 2011b; Figure 2). Although the
overall prevalence of the BRAFV600E mutation in PTC worldwide
is relatively high (Xing, 2007), the prevalence of this mutation
in PTMC is generally much lower in many parts of the world
(Lupi et al., 2007; Ugolini et al., 2007; Frasca et al., 2008) and as
low as 18% in PTMC less than 5mm in diameter (Ugolini et al.,
2007). Excluding the areas in Korea where the BRAFV600E muta-
tion in PTMC is high (Xing, 2007), the overall frequency of the
BRAFV600E mutation in PTMC is around 30% (Xing, 2007). Lee
et al. (2009) studied the clinico-pathological characteristics and
FIGURE 2 | BRAF
V600E triggers a cascade that leads to human papillary
thyroid microcarcinoma (PTMC) proliferation.The constitutive kinase
activity of BRAF
V600E phosphorylates and activates MEK1/2.
Phospho-MEK1/2 induces hyperphosphorylation of ERK1/2 which
translocates into the nucleus, triggering cell cycle progression, and
abnormal cell proliferation by up-regulating cyclins (e.g., Cyclin D1) crucial
for the checkpoint machinery in G1–S phases and inhibiting anti-cell cycle
cyclins (e.g., p27). Up-regulation of cyclins (e.g., Cyclin D1) leads to
hyper-proliferation of papillary thyroid microcarcinoma cells and increase in
papillae size.
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theBRAFV600Emutationalstatusof64casesofPTMCs.BRAFV600E
mutation was detected in 37.5% of PTMCs. BRAFV600E-positive
PTMCs exhibited signiﬁcantly more features of aggressiveness
(advanced disease stages, extra thyroidal extension, and nodal
metastasis) than PTMCs without the V600E mutation, indicating
thatBRAFV600E maybeamarkerof aggressivenessandtumorpro-
gression from PTMC to PTC. Fifty percent of BRAFV600E-positive
PTMCswerestageIIIorIV.ThesedataindicatethattheBRAFV600E
mutationmightbeamolecularmarkerof tumorinvasivenessand,
moreover,thatthisrelationshipisindependentof tumorsize(e.g.,
greater than 1.1cm vs. less than 1cm).
Recently, Niemeier et al. (2011) analyzed a group of aggressive
PTMCselectedbasedonthepresenceof lymphnodemetastasisor
tumor recurrence and compared with a group of non-aggressive
PTMC. The groups were matched for age,sex,and tumor size,but
withnoextrathyroidalspread(signiﬁcantlymoreprevalentinthe
aggressive group). Importantly,these authors detected BRAFV600E
in 77% of aggressive and 32% of non-aggressive PTMCs, sug-
gesting that the V600E mutation may be a marker of invasiveness
and,togetherwithhisto-pathologicfeaturesofaggressiveness,may
allow clinical risk stratiﬁcation of PTMCs.
The BRAFV600E mutation has been correlated with multifocal-
ity pathologic features in thyroid cancers (Xing, 2007). As is the
case for PTC, the importance of the distinction between multifo-
calindependentprimary(IP)PTMCandPTMCwithintrathyroid
metastasisisunclear.IncidentalPTMCcanbemultifocal(Linetal.,
2008) and associated with lymph node metastases and increased
neck lymph nodes recurrence after surgical treatment. Lin et al.
(2008)foundthattheincidenceoflymphnodemetastasisformul-
tifocal PTMC was 42.9%,similar to previous studies (David et al.,
1992;Rodriguezetal.,1997;Baudinetal.,1998;Aremetal.,1999).
Lin et al. also found that a high percentage (75%) of PTMC with
intrathyroid metastasis were positive for lymph node metastasis,
whilenopatientswithmultifocalIPPTMChadmetastaticdisease.
ThissuggeststhatitisimportanttoseparatePTMCwithintrathy-
roidmetastasisfrommultifocalIPtumors.Inthisstudy,about50%
of multifocal PTMCs showed intrathyroidal metastasis; the mole-
cular proﬁle of this group of PTMCs was characterized by loss of
heterozygosities(LOHs)atchromosomes1p36,18q21,and22q13,
and/or BRAFV600E mutation, suggesting that both different chro-
mosomal losses and point mutations in the BRAF gene could be
important pathological events in the origin of multifocal PTMC.
In summary, there is good evidence that BRAFV600E-positive
PTMC are more likely to have a poor prognosis and therefore, it
seems reasonable to be more aggressive in treating patients with
PTMC carrying the BRAFV600E mutation. Soares and Sobrinho-
Simoes (2011) recently suggested that genetic screening for the
BRAFV600E mutation might also help assess risk stratiﬁcation and
manage patients with PTMC. PTMC without BRAFV600E may be
conservatively managed unless the presence of other markers of
poor prognosis indicate a more aggressive therapeutic approach
(Xing, 2009).
MOLECULAR PATHWAYS IN PTMC
Since most PTMC progress very slowly while others show more
aggressive behavior, it would be clinically relevant to determine a
gene signature that can predict tumor aggressiveness. Few studies
have focused on the molecular pathways that underlie the patho-
biology of PTMC. Kim et al. (2010) recently performed oligonu-
cleotide array analysis of PTMC and found that cell adhesion
moleculeswereup-regulatedinPTMC.Inaddition,theyfoundno
differences in gene expression between PTMC and PTC, suggest-
ing that some PTMC may not be occult indolent thyroid cancers
but are an earlier stage of PTC.
Min et al. (2008) found that PTMC with extra thyroidal exten-
sion and multifocality exhibited signiﬁcant expression of S100A4
and that its expression predicted lymph node metastasis. S100A4
(Garrett et al., 2006) is a member of the S100 family of calcium-
binding proteins, which includes metastasin, ﬁbroblast-speciﬁc
protein,pEL-98,18A2,CAPL,and calvasculin. In vitro and in vivo
studies in rodents have provided evidence that S100A4 is directly
involved in tumor progression and metastasis, and promotes
angiogenesis.Therefore,preoperativeevaluationof theexpression
of S100A4 in cytological specimens should be helpful in guiding
therapy for patients with PTMCs. S100A4 immunoreactivity may
predict lymph node metastasis in PTMC and might therefore be
useful as an immunohistochemical marker to distinguish between
more aggressive PTMC and clinically indolent PTMC.
TARGETED THERAPIES WITH SELECTIVE AND
NON-SELECTIVE INHIBITORS OF BRAFV600E
Chemotherapies for metastatic thyroid carcinomas have been of
limited effectiveness. Therefore, novel therapies are needed to
improve disease outcome for patients with these cancers. Stud-
ies based on preclinical models of targeted therapies highlight the
importance of individualized genomic proﬁling to guide patient
selection for inclusion in clinical trials.
Some drugs that target the BRAFV600E oncoprotein kinase
have recently begun clinical trials in patients with melanoma.
Selective pharmacologic targeting of BRAFV600E may prove effec-
tive for treating patients with PTC harboring this mutation. For
example, PLX4720 and PLX4032 are novel orally available selec-
tive small molecule inhibitors speciﬁcally designed to insert into
the ATP-binding site and trap oncogenic BRAFV600E in an inac-
tive conformation (Tsai et al., 2008; Bollag et al., 2010). These
compounds inhibit BRAFV600E kinase activity in melanoma, thy-
roid cancer, and colorectal cancer cells (Tsai et al., 2008; Nucera
et al.,2010). PLX4032 (Vemurafenib) induced complete or partial
tumorregressionin81%of patientsenrolledforphaseI–IIclinical
trial who had melanoma with the BRAFV600E mutation (Flaherty
et al., 2010). In addition, it signiﬁcantly improved rates of overall
survival and progression-free survival (74%) in phase III clinical
trials in BRAFV600E-positive melanoma patients (Chapman et al.,
2011). The effect of PLX4720 in a preclinical model of metastatic
humanthyroidcancersuggeststhattheseinhibitorsmightbeeffec-
tive for treating patients with BRAFV600E-positive thyroid cancers
that are refractory to conventional therapy (Nucera et al.,2010).
Interestingly, overexpression of angiogenic signaling cascade
pathwayshasbeendescribedinhumanPTC,andpreclinicalmod-
els have shown that inhibition of key molecules (i.e., protein
kinases) in these pathways can have anti-tumor effects (Gild et al.,
2011). Some of these kinase inhibitors have now been tested in
clinical trials, with modest results. For example, Sorafenib was
designed as a c-RAF inhibitor; however, it has been reported to
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target other kinases, including vascular endothelial growth factor
receptors (VEGFR) and BRAFV600E, therefore, it has been classi-
ﬁed as non-selective inhibitor of BRAFV600E. Sorafenib has been
assessed clinically in patients with BRAFV600E-positive or geneti-
cally unknown advanced melanoma and did not show any beneﬁt
in those clinical trials (Hauschild et al., 2009; Ott et al., 2010;
Caroniaetal.,2011).Additionally,inphaseI–IIclinicaltrials,only
15% of patients with metastatic PTC showed a partial response to
Sorafenib (Kloos et al.,2009; Caronia et al.,2011).
Although only a small percentage of all PTMC are metasta-
tic,∼77% of BRAFV600E-positive PTMC show features associated
with aggressiveness (i.e.,extra thyroidal extension;Niemeier et al.,
2011). For these tumors, targeted therapies based on selective
inhibitors of BRAFV600E could be effective in the near future.
CONCLUSION AND PERSPECTIVES
The management and treatment of malignant thyroid micro nod-
ules (i.e., PTMC) can be a challenge for physicians. Most PTMC
areindolentandhaveanexcellentprognosis;however,asubgroup
showsanaggressivebiologicalandclinicalbehaviorsimilartoPTC.
While additional robust prospective studies are required, there
is now a body of evidence suggesting that BRAFV600E-positive
PTMCs show aggressive behavior, whereas BRAFV600E-negative
PTMCs have a good prognosis. This suggests that it will be valu-
able to consider the BRAFV600E mutation as a prognostic marker
ofPTMCaggressivenessandtoundertakeprospectivestudieswith
systematic screening for the BRAFV600E mutation and long-term
follow-up to validate this marker of tumor aggressiveness.
A validated marker would help endocrinologists and oncolo-
gistsstratifyclinicalriskinPTMC.Although,additionalbiological
studies are needed to address deﬁnitively whether PTMC is an
indolent cancer or an early stage of PTC,current clinical and mol-
ecular data suggest that patients with PTMCs that harbor the
BRAFV600E mutation and exhibit aggressive clinical–pathologic
features may beneﬁt from treatment with BRAFV600E-selective
inhibitors. There is sufﬁcient promising preclinical experimen-
tal data to suggest that physicians could begin to test such tar-
geted treatments now, preferably in the context of a prospec-
tive clinical trial following patients with aggressive BRAFV600E-
expressing PTMC.
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